UC Davis

UC Davis Previously Published Works

Title

Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats.

Permalink

<https://escholarship.org/uc/item/1x51c5hs>

Journal

Journal of veterinary pharmacology and therapeutics, 39(5)

ISSN

0140-7783

Authors

Pypendop, BH
Honkavaara, J
Ilkiw, JE

Publication Date

2016-10-01

DOI

10.1111/jvp.12302

Peer reviewed

1Pharmacokinetics of dexmedetomidine, MK-467, and their combination following
2intravenous administration in male cats

3Short title: PK of IV dexmedetomidine and MK-467 in cats

4Bruno H. Pypendop*, DrMedVet, DrVetSci, Dipl. ACVAA; Juhana Honkavaara[†], DVM,
5PhD, Jan E. Ilkiw*, BVSc, PhD.

6*Department of Surgical and Radiological Sciences, School of Veterinary Medicine,
7University of California, Davis, California, USA and [†]Department of Equine and Small
8Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Finland.

9

10Corresponding author: Bruno Pypendop, Department of Surgical and Radiological
11Sciences, School of Veterinary Medicine, University of California, One Shields Avenue,
12Davis, CA 95616.

13Email: bhpypendop@ucdavis.edu

14Fax: 209 396 2822

15

16Abstract

17This study characterized the pharmacokinetics of dexmedetomidine, MK-467, and their
18combination following intravenous bolus administration to cats. Seven 6 to 7 year old
19male neutered cats, weighting 5.1 ± 0.7 kg were used in a randomized, cross-over design.
20Dexmedetomidine [12.5 (D12.5) and 25 (D25) $\mu\text{g/kg}$], MK-467 [300 $\mu\text{g/kg}$ (M300)] or
21dexmedetomidine (25 $\mu\text{g/kg}$) and MK-467 [75, 150, 300 or 600 $\mu\text{g/kg}$ - only the plasma
22concentrations in the 600 $\mu\text{g/kg}$ group (D25M600) were analyzed] were administered
23intravenously, and blood was collected until 8 hours thereafter. Plasma drug
24concentrations were analyzed using liquid chromatography/mass spectrometry. A two-
25compartment model best fitted the data. Median (range) volume of the central
26compartment (mL/kg), volume of distribution at steady-state (mL/kg), clearance
27(mL/min/kg) and terminal half-life (min) were 342 (131-660), 829 (496-1243), 14.6 (9.6-
2822.7) and 48 (40-69) for D12.5; 296 (179-982), 1111 (908-2175), 18.2 (12.4-22.9), and
2952 (40-76) for D25; 653 (392-927), 1595 (1094-1887), 22.7 (18.5-36.4), and 48 (35-60)
30for dexmedetomidine in D25M600; 117 (112-163), 491 (379-604), 3.0 (2.0-4.5), and 122
31(99-139) for M300; and 147 (112-173), 462 (403-714), 2.8 (2.1-4.8), and 118 (97-172)
32for MK-467 in D25M600. MK-467 moderately but statistically significantly affected the
33disposition of dexmedetomidine, whereas dexmedetomidine minimally affected the
34disposition of MK-467.

35**Keywords:** Cats, pharmacokinetics, dexmedetomidine, MK-467, intravenous

37Introduction

38Dexmedetomidine, the active isomer in the racemic medetomidine, is an alpha-2
39adrenoceptor agonist, and is widely used to produce sedation and analgesia, or as
40premedication prior to general anesthesia, in a variety of species, including cats
41(Granholm et al., 2006; McSweeney et al., 2012). Like other drugs in this class,
42medetomidine and dexmedetomidine cause vasoconstriction, bradycardia and decreased
43cardiac output (Lamont et al., 2001; Selmi et al., 2003; Pypendop et al., 2011). These
44effects may be detrimental, particularly in older or sick cats, and may limit the clinical
45use of dexmedetomidine in these patients.

46MK-467, previously known as L-659,066 is an alpha-2 adrenoceptor antagonist;
47however, contrary to other alpha-2 antagonists, it does not appear to cross the blood-brain
48barrier (Clineschmidt et al., 1988). Because the desirable effects from alpha-2 agonists
49(sedation, analgesia) are mediated at the level of the central nervous system, but the
50cardiovascular effects (vasoconstriction, bradycardia) are, at least in part, mediated
51peripherally (i.e. outside of the central nervous system), combining medetomidine or
52dexmedetomidine with MK-467 has been proposed to decrease the vasoconstriction and
53bradycardia, while minimally affecting the sedative (and presumably analgesic) effect.
54Such benefits have been demonstrated in dogs, sheep and horses (Pagel et al., 1998;
55Enouri et al., 2008; Honkavaara et al., 2008; Raekallio et al., 2010; Honkavaara et al.,
562011; Restitutti et al., 2011; Rolfe et al., 2012; Vainionpaa et al., 2013).

57Dexmedetomidine likely affects its own disposition by producing bradycardia and
58vasoconstriction (Dutta et al., 2000; Pypendop et al., 2013). These effects would be
59expected to decrease the volume of distribution and clearance, resulting in longer

terminal half-life and increased exposure. If MK-467 prevents or decreases the magnitude of dexmedetomidine-induced cardiovascular depression, it would affect the disposition of dexmedetomidine, as has been reported in dogs (Honkavaara et al., 2012).

The aim of this study was to characterize the pharmacokinetics of dexmedetomidine, MK-467, and their combination, following IV¹ administration to cats. We hypothesized that MK-467 would significantly alter the pharmacokinetics of dexmedetomidine (i.e. would increase clearance/decrease exposure), while dexmedetomidine would not significantly alter the disposition of MK-467.

Materials and methods

The results reported here were obtained as part of a larger study, aiming at defining the optimal dose of MK-467 preventing dexmedetomidine-induced bradycardia without affecting dexmedetomidine-induced sedation (Honkavaara et al., 2016). The methods and results for heart rate measurement and sedation are presented in detail elsewhere.

Animals

Seven healthy 6- to 7-year old neutered male cats were used in the study (mean $\pm$ SD body weight 5.1 ± 0.7 kg, body condition score 5/9). The study was approved by the Institutional Animal Care and Use Committee at the University of California, Davis. All cats were acclimatized to laboratory conditions and handling prior to commencing the study.

Instrumentation

Prior to the study, all cats were anesthetized for implantation of a subcutaneous telemetric ECG and blood pressure transmitter and vascular access port; the catheters of the

¹ Intravenous

82transmitter and port were placed in a carotid artery. However, due to technical problems
83with the vascular access ports early in the study, it was decided not to use them for blood
84collection.

85At least 12 hours prior to the study, cats were anesthetized with isoflurane in oxygen for
86placement of a jugular and medial saphenous venous catheter. The former was used for
87blood sample collection, and the latter for drug administration. Catheter insertion sides
88(left / right) were alternated during the course of the investigation.

89*Treatments*

90Each cat received a total of seven treatments: dexmedetomidine at two doses (12.5 and 25
91 $\mu\text{g kg}^{-1}$; D12.5 and D25, respectively), MK-467 (Vetcare Ltd, Mäntsälä, Finland) alone
92($300 \mu\text{g kg}^{-1}$; M300), and dexmedetomidine ($25 \mu\text{g/kg}$) combined with MK-467 (75, 150,
93300 and $600 \mu\text{g/kg}$; D25M75, D25M150, D25M300 and D25M600, respectively). The
94order of treatments was randomized according to a computer-generated randomization
95list (www.randomizer.org) and there were at least two weeks between successive
96treatments. MK-467, in powder form, was dissolved in sterile 0.9% saline to a
97concentration of 2 mg/mL and aspirated into a syringe through a $0.2 \mu\text{m}$ filter
98(Fisherbrand, Fischer Scientific, PA, USA). Dexmedetomidine was diluted with 0.9%
99saline to a concentration of $100 \mu\text{g/mL}$. Combination treatments were mixed in the same
100syringe, and all drugs were diluted to a final volume of 3 mL with 0.9% saline.

101Treatments were prepared less than an hour prior to administration as an IV bolus.

102*Blood sampling*

103Blood samples (2 mL) were obtained from the jugular catheter prior to drug
104administration, and 1, 2, 4, 8, 15, 30, 60, 120, 240, and 480 minutes following drug

105administration. Blood was transferred into tubes containing EDTA and immediately
106placed on ice. Blood was centrifuged within 30 minutes of collection, the plasma
107separated and frozen at -20°C until analyzed for dexmedetomidine and/or MK-467
108concentrations.

109*Drug analysis*

110Dexmedetomidine and MK-467 concentrations were determined in protein-precipitated
111plasma samples using liquid chromatography/mass spectrometry, according to previously
112reported methods (Escobar et al., 2012; Honkavaara et al., 2012). The limit of
113quantitation was 0.1 ng/mL for both dexmedetomidine and MK-467. For
114dexmedetomidine, accuracy (% nominal concentration) was verified at 0.3, 5 and 30
115ng/mL and ranged from 92 to 111%. Intra-assay and inter-assay precision, verified at the
116same concentrations, ranged from 2 to 13% and from 6 to 16%, respectively. Based on
117the pharmacodynamic results (data presented elsewhere), the D25M600 was considered
118the combination group of interest, and plasma dexmedetomidine and MK-467
119concentrations were determined for that combination only (in addition to the D12.5, D25
120and M300 groups).

121*Pharmacokinetic analysis*

122All pharmacokinetic analyses were performed using Phoenix WinNonlin 6.2 (Certara,
123Princeton, NJ). Nonlinear least squares regression was performed on the plasma
124dexmedetomidine concentration-time data. Data were weighted by the reciprocal of the
125observed plasma concentrations squared (D12.5, dexmedetomidine in D25M600) or the
126reciprocal of the predicted concentrations squared (D25, M300, MK-467 in D25M600)
127and fitted to 2-, and 3-compartment models with bolus input into, and elimination from

the central compartment. The appropriate model was selected by observation of the residuals plot and by use of Akaike's information criterion. Parameters estimated by the model were A, B, α and β in the equation $C_t = A' e^{-\alpha t} + B' e^{-\beta t}$, where C_t is the plasma drug concentration at time t. Other pharmacokinetic parameters were calculated by use of standard pharmacokinetic equations.

Protein binding

Protein binding of dexmedetomidine and MK-467 was determined using equilibrium dialysis. Briefly, MK-467 and dexmedetomidine were added to cat plasma to reach concentrations of 0.1, 1, and 10 $\mu\text{g/mL}$ for MK-467, with or without 20 ng/mL dexmedetomidine, and 5, 20, and 100 ng/mL for dexmedetomidine; protein binding of dexmedetomidine 20 ng/mL was also determined with 0.1, 1, or 10 $\mu\text{g/mL}$ MK-467. Samples were incubated for 4 hours with continuous shaking at 37°C in an equilibrium dialysis device using phosphate buffered saline as a receiver side solution. After incubation, the plasma phase was diluted with an equal volume of phosphate buffered saline, and the phosphate buffered saline phase was diluted with an equal volume of blank plasma. All samples were protein-precipitated using acetonitrile. After centrifugation the supernatants were analyzed in triplicate for dexmedetomidine and/or MK-467 concentrations using liquid chromatography/mass spectrometry. The unbound drug fraction (%) was calculated as $100 \times \text{peak area in phosphate buffered saline phase} / \text{peak area in plasma phase}$.

Statistical analysis

Dexmedetomidine pharmacokinetic parameters were compared between the D25 and D25M600 groups using the Wilcoxon signed rank test for paired data. One-tailed tests

151 were used, to match our stated hypothesis that MK-467 increased the clearance
152 of/decreased the exposure to dexmedetomidine. MK-467 pharmacokinetic parameters
153 were compared between the M300 and D25M600 groups, following correction for the
154 difference in dose where appropriate, using the two-tailed Wilcoxon signed rank test for
155 paired data. In addition, plasma dexmedetomidine concentration at time 0 (C_0) and area
156 under the time-dexmedetomidine concentration curve (AUC) were tested for
157 bioequivalence between D12.5 and D25M600, and between D25 and D25M600.
158 Similarly, MK-467 C_0 and AUC, indexed to the dose, were tested for bioequivalence in
159 the M300 and D25M600 groups. Bioequivalence was defined according to the WHO
160 Guidelines on Evaluation of Similar Biotherapeutic Products² and the EMA Guideline on
161 the Investigation of Bioequivalence³, in which the 90% confidence interval (CI) for the
162 ratio of the test (D25M600) and reference (D12.5, D25 or M300, respectively) products
163 should fall within the 80-125% range. Significance was set at $P < 0.05$. Data is presented
164 as median (range) except where specified otherwise.

165 Results

166 Due to a treatment error, data was available for 6 cats in the D25 group, and 7 cats in the
167 other groups. A 2-compartment model with bolus input into, and elimination from the
168 central compartment best fitted the time-plasma concentration data for dexmedetomidine
169 (Figure 1) and MK-467 (Figure 2) in all treatment groups. Pharmacokinetic parameters
170 for dexmedetomidine in D12.5, D25 and D25M600 are presented in Table 1.

22 http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_F
30 [OR WEB 22APRIL2010.pdf](http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_F), accessed on 7/30/2015.

43 [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf)
5 [WC500070039.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf), accessed on 7/30/2015

Pharmacokinetic parameters for MK-467 in M300 and D25M600 are presented in Table 2. The disposition of dexmedetomidine was significantly affected by the co-administration of MK-467, as shown by significant differences in A ($p = 0.0313$), AUC ($p = 0.0469$), area under the first moment curve ($p = 0.0488$), clearance ($p = 0.0469$), and C_0 ($p = 0.0283$). For MK-467, K_{10} was significantly larger in M300 compared to D25M600 ($p = 0.0234$); no other significant difference was found. Dexmedetomidine 25 $\mu\text{g/kg}$ combined with MK-467 600 $\mu\text{g/kg}$ was not bioequivalent to either dexmedetomidine 12.5 $\mu\text{g/kg}$ or 25 $\mu\text{g/kg}$ [ratio of AUC (90% CI) 113% (79-162%) and 74% (56-98%) for D25M600/D12.5 and D25M600/D25, respectively; ratio of C_0 98% (57-166%) and 55% (31-97%) D25M600/D12.5 and D25M600/D25, respectively]. MK-467 600 $\mu\text{g/kg}$ combined with dexmedetomidine 25 $\mu\text{g/kg}$ fulfilled the criteria for bioequivalence with MK-300 $\mu\text{g/kg}$ based on AUC/dose [ratio (90% CI) 103% (97-109%)] but not on C_0 [ratio (90% CI) 87% (78-97%)].

Results for protein binding of dexmedetomidine and MK-467 are presented in Table 3.

Discussion

In this study, the disposition of dexmedetomidine was influenced by the co-administration of MK-467. This is presumably related to the antagonism of dexmedetomidine-induced bradycardia and vasoconstriction as has been reported in other species, influencing the distribution and metabolism of dexmedetomidine (Enouri et al., 2008; Honkavaara et al., 2008; Raekallio et al., 2010; Honkavaara et al., 2011; Rolfe et al., 2012; Vainionpää et al., 2013). The changes in the pharmacokinetics of dexmedetomidine observed with co-administration of MK-467 are in agreement with a previous study in dogs, in which co-administration of MK-467 halved the area under the

194time-plasma dexmedetomidine concentration curve, and doubled the volume of
195distribution of dexmedetomidine (Honkavaara et al., 2012). However, the changes seen in
196this study were more modest in comparison; median dexmedetomidine AUC was
197approximately 20% smaller when MK-467 was co-administered than when it was not,
198and median volume of distribution was approximately 44% larger when MK-467 was co-
199administered, although the difference was not statistically significant. Several factors may
200have contributed to these differences between dogs and cats. First, the ratio of doses for
201MK-467 and dexmedetomidine was 24:1 in this study, and 25-75:1 in the dog study. It is
202possible that the lower MK-467:dexmedetomidine dose ratio used here resulted in less
203complete antagonism of dexmedetomidine-induced peripheral cardiovascular effects.
204Second, the previous study compared the pharmacokinetics of dexmedetomidine, with or
205without co-administration of MK-467, for 90 minutes following administration,
206compared to 8 hours in this study. At the dose used, the cardiovascular effects of
207dexmedetomidine are expected to last only for approximately 2-3 hours, therefore the
208magnitude of the difference would be expected to decrease as drug concentration data is
209obtained over a longer time. Third, the dose of dexmedetomidine in this study (25 µg/kg)
210was 2.5 time larger than the dose in the previous study, possibly resulting in larger
211decreases in heart rate and increases in systemic vascular resistance, which, when
212coupled with a lower MK-467:dexmedetomidine dose ratio may have resulted in less
213complete peripheral antagonism of these changes. Finally, the differences may be simply
214related to the fact that 2 different species were studied.

215Dexmedetomidine administration appeared to have minimal influence on the disposition
216of MK-467 in cats. The reason for the significant difference in K_{10} is unclear, but may be

217related to the fact that MK-467 incompletely antagonized dexmedetomidine-induced
218cardiovascular effects, and that these cardiovascular effects influence the rate at which
219MK-467 was eliminated. Alternatively, the higher dose of MK-467 in the combination
220group may be responsible for the difference. In any case, the magnitude of the difference
221was small, and while clearance was also slightly larger for MK-467 alone, the difference
222did not reach statistical significance. Interestingly, MK-467 combined with
223dexmedetomidine did fulfill the criteria for bioequivalence with MK-467 alone
224(following correction for the difference in dose) based on exposure (i.e. AUC) but not
225based on C_0 . Again, the reason for this lack of bioequivalence is unclear; if related to
226partial antagonism of early dexmedetomidine-induced cardiovascular effects, one would
227expect that dose-corrected C_0 would be larger for MK-467 combined with
228dexmedetomidine than for MK-467 alone, as the lower cardiac output due to lower heart
229rate and larger increase in systemic vascular resistance following dexmedetomidine
230would be expected to cause a decrease in the volume of the central compartment.
231However, in this study, dose-corrected C_0 was larger for MK-467 alone. MK-467 may
232have dose-dependent pharmacokinetics in cats, as to the author's knowledge, this is the
233first study in this species, and only one dose of MK-467 was tested; however, dose-
234dependent pharmacokinetics typically result in differences in AUC. Finally, the reason for
235the lack of acceptance of bioequivalence in C_0 may be related to lack of statistical power:
236the lower 90% CI fell just outside of the 80-125% range, and this is likely related to the
237small study sample, as a larger sample would likely result in a smaller CI around the
238mean, and would likely fall within the 80-125% range. It should be noted that 7 subjects
239would be considered too low based on regulatory agency recommendations to test

240 bioequivalence; therefore, rejection of bioequivalence should be interpreted with caution.
241 A larger number of subjects would tend to narrow the confidence interval, and it is
242 possible that parameters for which the ratio is close to 100%, bioequivalence would be
243 demonstrated in a larger study. However, it is unlikely that a larger study would change
244 the findings for parameters for which bioequivalence was confirmed.

245 Plasma protein binding was high for dexmedetomidine and moderate for MK-467. In
246 addition, while no statistical analysis was conducted on protein binding data, due to
247 triplicate determination in a single sample at each concentration, plasma protein binding
248 for either drug appeared to be independent of the presence of the other drug. Within the
249 range of concentrations studied, plasma protein binding appeared concentration-
250 independent for dexmedetomidine, whereas it was lower at the lowest MK-467
251 concentration examined. The reasons for this finding are unclear, but it is suspected to be
252 related to the assay, as a consistent carryover was observed in the chromatographic
253 system during MK-467 analyses, and this may have influenced the observed binding at
254 the lowest MK-467 concentration. Overall, total drug concentrations (as measured in this
255 study) are expected to be a good predictor of the free, active drug concentrations.

256 The dose of dexmedetomidine used in this study (25 µg/kg) was selected to produce
257 profound sedation for approximately 2 hours, based on the results of a previous study
258 (Pypendop & Ilkiw, 2014b). The additional dexmedetomidine group (D12.5) was selected
259 based on the dog study, in which exposure to dexmedetomidine was approximately
260 halved by the addition of MK-467, in an attempt to include a dexmedetomidine alone
261 group with similar exposure to dexmedetomidine as in the group including MK-467
262 (Honkavaara et al., 2012). However, as illustrated by the lack of bioequivalence between

263the D25M600 and either the D12.5 or D25 groups, the exposure to dexmedetomidine
264when combined with MK-467 at the dose used was not similar to that following 12.5
265µg/kg dexmedetomidine. Nevertheless, the ratios for AUC and C₀ suggest that, overall,
266the disposition of 25 µg/kg dexmedetomidine combined with 600 µg/kg MK-467 was
267more similar to the disposition of 12.5 µg/kg than that of 25 µg/kg dexmedetomidine
268alone. The dose of MK-467 (600 µg/kg) in the combination was selected based on the
269pharmacodynamic part of the study, as it was the dose achieving the largest reduction in
270dexmedetomidine-induced bradycardia (Honkavaara et al., 2016). The dose of MK-467
271alone (300 µg/kg) was selected because it was an intermediate dose in the planned
272combination groups.

273The pharmacokinetics of dexmedetomidine in cats following bolus administration of 5,
27420, and 50 µg/kg have been previously reported (Pypendop & Ilkiw, 2014a). A 3-
275compartment model best fitted the time-concentration data following 20 and 50 µg/kg,
276whereas a 2-compartment model best fitted the data in this study. Overall, the disposition
277of dexmedetomidine following 20 µg/kg was fairly similar to that in this study. When
278compared to the 25 µg/kg group from the present investigation, median AUC and
279clearance were 11% larger and 30% lower in the previous study, respectively. Terminal
280half-life was 52 min in this study and 56 min in the previous study. Volume of
281distribution was approximately half in the previous study compared to this study. The
282methods in the previous study were similar to those in this study; however 5 female
283spayed cats were used, compared to 7 male cats in this study. It is possible that
284differences in body composition between the 2 study groups account for some of the
285differences observed.

286This study has several limitations. The study sample was small, resulting in limited
287statistical power; this was worsened for the D25 group due to the treatment error. Due to
288the small sample, it was decided that non-parametric statistics were preferable, again
289decreasing the likelihood of reaching statistical significance. Only one dose of
290dexmedetomidine and MK-467 were used in combination, and the dose of MK-467 alone
291was different from the dose used in the combination. It is possible that the
292pharmacokinetic interaction between dexmedetomidine and MK-467 would be different
293at different doses or different dose ratios. Finally, only male neutered cats were used; to
294the authors' knowledge, there is no data available on sex differences in the disposition of
295either dexmedetomidine or MK-467. It is therefore possible that the findings would be
296different in female cats.

297In conclusion, the pharmacokinetics of dexmedetomidine and MK-467, alone and in
298combination, following intravenous bolus administration in male cats were described. At
299the doses used, co-administration of MK-467 moderately influenced the disposition of
300dexmedetomidine, whereas co-administration of dexmedetomidine minimally influenced
301the disposition of MK-467.

302**Acknowledgements**

303This study was funded by the Morris Animal Foundation. MK-467 was provided for free
304by Vetcare Ltd., Mäntsälä, Finland. The authors thank Dr. Juho Hokkanen, Admescope
305Ltd., Oulu, Finland, for the protein binding determinations.

306

307References

- 308Clineschmidt, B.V., Pettibone, D.J., Lotti, V.J., Hucker, H.B., Sweeney, B.M., Reiss,
309 D.R., Lis, E.V., Huff, J.R. & Vacca, J. (1988). A peripherally acting alpha-2
310 adrenoceptor antagonist: L-659,066. *Journal of Pharmacology and Experimental*
311 *Therapeutics*, 245, 32-40.
- 312Dutta, S., Lal, R., Karol, M.D., Cohen, T. & Ebert, T. (2000). Influence of cardiac output
313 on dexmedetomidine pharmacokinetics. *Journal of Pharmacological Science*, 89,
314 519-527.
- 315Enouri, S.S., Kerr, C.L., McDonell, W.N., O'Sullivan, M.L. & Neto, F.J. (2008). Effects
316 of a peripheral alpha2 adrenergic-receptor antagonist on the hemodynamic
317 changes induced by medetomidine administration in conscious dogs. *American*
318 *Journal of Veterinary Research*, 69, 728-736.
- 319Escobar, A., Pypendop, B.H., Siao, K.T., Stanley, S.D. & Ilkiw, J.E. (2012).
320 Pharmacokinetics of dexmedetomidine administered intravenously in isoflurane-
321 anesthetized cats. *American Journal of Veterinary Research*, 73, 285-289.
- 322Granholm, M., McKusick, B.C., Westerholm, F.C. & Aspegren, J.C. (2006). Evaluation
323 of the clinical efficacy and safety of dexmedetomidine or medetomidine in cats
324 and their reversal with atipamezole. *Veterinary Anaesthesia and Analgesia*, 33,
325 214-223.
- 326Honkavaara, J., Pypendop, B.H., Turunen, H. & Ilkiw, J.E. (2016). The effect of MK-467,
327 a peripheral alpha2-adrenoceptor antagonist, on dexmedetomidine-induced
328 sedation and bradycardia after intravenous administration to conscious cats.
329 *Veterinary Anaesthesia and Analgesia*, In Press.

330 Honkavaara, J., Restitutti, F., Raekallio, M., Salla, K., Kuusela, E., Ranta-Panula, V.,
331 Rinne, V., Vainio, O. & Scheinin, M. (2012). Influence of MK-467, a peripherally
332 acting α_2 -adrenoceptor antagonist on the disposition of intravenous
333 dexmedetomidine in dogs. *Drug Metabolism and Disposition*, 40, 445-449.

334 Honkavaara, J.M., Raekallio, M.R., Kuusela, E.K., Hyvarinen, E.A. & Vainio, O.M.
335 (2008). The effects of L-659,066, a peripheral α_2 -adrenoceptor antagonist, on
336 dexmedetomidine-induced sedation and bradycardia in dogs. *Veterinary*
337 *Anaesthesia and Analgesia*, 35, 409-413.

338 Honkavaara, J.M., Restitutti, F., Raekallio, M.R., Kuusela, E.K. & Vainio, O.M. (2011).
339 The effects of increasing doses of MK-467, a peripheral α_2 -adrenergic
340 receptor antagonist, on the cardiopulmonary effects of intravenous
341 dexmedetomidine in conscious dogs. *Journal of Veterinary Pharmacology and*
342 *Therapeutics*, 34, 332-337.

343 Lamont, L.A., Bulmer, B.J., Grimm, K.A., Tranquilli, W.J. & Sisson, D.D. (2001).
344 Cardiopulmonary evaluation of the use of medetomidine hydrochloride in cats.
345 *American Journal of Veterinary Research*, 62, 1745-1749.

346 McSweeney, P.M., Martin, D.D., Ramsey, D.S. & McKusick, B.C. (2012). Clinical
347 efficacy and safety of dexmedetomidine used as a preanesthetic prior to general
348 anesthesia in cats. *Journal of the American Veterinary Medical Association*, 240,
349 404-412.

350 Pagel, P.S., Proctor, L.T., Devcic, A., Hettrick, D.A., Kersten, J.R., Tessmer, J.P., Farber,
351 N.E., Schmeling, W.T. & Warltier, D.C. (1998). A novel α_2 -adrenoceptor
352 antagonist attenuates the early, but preserves the late cardiovascular effects of

353 intravenous dexmedetomidine in conscious dogs. *Journal of Cardiothoracic and*
 354 *Vascular Anesthesia*, 12, 429-434.

355 Pypendop, B.H., Barter, L.S., Stanley, S.D. & Ilkiw, J.E. (2011). Hemodynamic effects of
 356 dexmedetomidine in isoflurane-anesthetized cats. *Veterinary Anaesthesia and*
 357 *Analgesia*, 38, 555-567.

358 Pypendop, B.H., Escobar, A., Siao, K.T., Stanley, S.D. & Ilkiw, J.E. (2013). Effect of
 359 dexmedetomidine on its clearance: a pharmacokinetic model. *Journal of*
 360 *Veterinary Pharmacology and Therapeutics*, 36, 89-91.

361 Pypendop, B.H. & Ilkiw, J.E. (2014a). Pharmacokinetics of dexmedetomidine after
 362 intravenous administration of a bolus to cats. *American Journal of Veterinary*
 363 *Research*, 75, 441-445.

364 Pypendop, B.H. & Ilkiw, J.E. (2014b). Relationship between plasma dexmedetomidine
 365 concentration and sedation score and thermal threshold in cats. *American Journal*
 366 *of Veterinary Research*, 75, 446-452.

367 Raekallio, M.R., Honkavaara, J.M. & Vainio, O.M. (2010). The effects of L-659,066, a
 368 peripheral alpha2-adrenoceptor antagonist, and verapamil on the cardiovascular
 369 influences of dexmedetomidine in conscious sheep. *Journal of Veterinary*
 370 *Pharmacology and Therapeutics*, 33, 434-438.

371 Restitutti, F., Honkavaara, J.M., Raekallio, M.R., Kuusela, E.K. & Vainio, O.M. (2011).
 372 Effects of different doses of L-659'066 on the bispectral index and clinical
 373 sedation in dogs treated with dexmedetomidine. *Veterinary Anaesthesia and*
 374 *Analgesia*, 38, 415-422.

375 Rolfe, N.G., Kerr, C.L. & McDonell, W.N. (2012). Cardiopulmonary and sedative effects
376 of the peripheral alpha2-adrenoceptor antagonist MK 0467 administered
377 intravenously or intramuscularly concurrently with medetomidine in dogs.
378 *American Journal of Veterinary Research*, 73, 587-594.

379 Selmi, A.L., Mendes, G.M., Lins, B.T., Figueiredo, J.P. & Barbudo-Selmi, G.R. (2003).
380 Evaluation of the sedative and cardiorespiratory effects of dexmedetomidine,
381 dexmedetomidine-butorphanol, and dexmedetomidine-ketamine in cats. *Journal*
382 *of the American Veterinary Medical Association*, 222, 37-41.

383 Vainionpaa, M.H., Raekallio, M.R., Pakkanen, S.A., Ranta-Panula, V., Rinne, V.M.,
384 Scheinin, M. & Vainio, O.M. (2013). Plasma drug concentrations and clinical
385 effects of a peripheral alpha-2-adrenoceptor antagonist, MK-467, in horses
386 sedated with detomidine. *Veterinary Anaesthesia and Analgesia*, 40, 257-264.

387

388

Table 1: Median (range) pharmacokinetic parameters for dexmedetomidine, following intravenous bolus administration of 12.5 µg/kg (D12.5), 25 µg/kg (D25), or 25 µg/kg dexmedetomidine combined with 600 µg/kg MK-467 (D25M600) in 7 cats. Due to a treatment error, data is available for 6 cats only in the D25 group.

Parameter	D12.5	D25	D25M600
A (ng/mL)	25 (12-78.7)	68.3 (17.1-115.8)	25.1 (14.8-42.4)*
B (ng/mL)	10.1 (2-19)	16.5 (8.4-23.7)	12.3 (9-21.5)
α (/min)	0.3 (0.03-1.49)	0.28 (0.1-1.08)	0.35 (0.11-1.01)
β (/min)	0.014 (0.01-0.017)	0.013 (0.009-0.017)	0.014 (0.012-0.02)
$t_{1/2\alpha}$ (min)	2.3 (0.5-23.1)	3.6 (0.6-6.7)	2 (0.7-6.4)
$t_{1/2\beta}$ (min)	48 (40-69)	52 (40-76)	48 (35-60)
V_1 (mL/kg)	342 (131-660)	296 (179-982)	653 (392-927)
V_2 (mL/kg)	588 (169-696)	744 (579-1193)	904 (496-1147)
V_{ss} (mL/kg)	829 (496-1243)	1111 (908-2175)	1595 (1094-1887)
CL (mL/min/kg)	14.6 (9.6-22.7)	18.2 (12.4-22.9)	22.7 (18.5-36.4)*
CL_D (mL/min/kg)	40.4 (2-153.9)	60.9 (20.4-163.4)	118.7 (37.6-247.5)
K_{10} (/min)	0.043 (0.025-0.083)	0.05 (0.023-0.106)	0.045 (0.025-0.052)
$K_{10} T_{1/2}$ (min)	16.3 (8.4-27.8)	14.9 (6.5-29.7)	15.3 (13.4-28.3)
K_{12} (/min)	0.142 (0.003-1.164)	0.176 (0.049-0.803)	0.182 (0.041-0.629)
K_{21} (/min)	0.086 (0.012-0.262)	0.07 (0.035-0.198)	0.128 (0.038-0.351)
C_0 (ng/mL)	36.5 (18.9-95.7)	86.2 (25.5-139.5)	38.3 (27-63.8)*
AUC (ng.min/mL)	858 (552-1304)	1382 (1090-2023)	1099 (686-1349)*
AUMC	61113 (26662-75576)	89045 (61595-	77430 (34348-
(ng.min ² /mL)		150187)	91517)*
MRT (min)	58 (48-73)	63 (53-95)	64 (46-81)

A, B: coefficients, α , β : exponents in the equations $C_t = A \times e^{-\alpha t} + B \times e^{-\beta t}$, where C_t is drug concentration at time t; $t_{1/2\alpha}$: distribution half-life; $t_{1/2\beta}$: elimination half-life; V_1 : apparent volume of the central compartment; V_2 : apparent volume of the peripheral compartment; V_{ss} : apparent volume of distribution at steady-state; CL: clearance; CL_D : distribution clearance; K_{10} , K_{12} , K_{21} : rate constants; C_0 : concentration at time 0; AUC: area under the plasma concentration curve; AUMC: area under the first moment curve; MRT: mean residence time. *Significantly ($P < 0.05$) different from D25 (only the D25 and D25M600 groups were compared).

Table 2: Median (range) pharmacokinetic parameters for MK-467, following intravenous bolus administration of 300 µg/kg (M300), or 600 µg/kg MK-467 combined with 25 µg/kg dexmedetomidine (D25M600) in 7 cats.

Parameter	M300	D25M600
A (ng/mL)	1933.9 (1379.6-2242.9)	2973.7 (2438-3974)
B (ng/mL)	562.5 (431.9-730.3)	1194.9 (731.7-1402.8)
α (/min)	0.29 (0.22-0.5)	0.37 (0.23-0.53)
β (/min)	0.006 (0.005-0.007)	0.006 (0.004-0.007)
$t_{1/2\alpha}$ (min)	2.4 (1.4-3.2)	1.9 (1.3-3.1)
$t_{1/2\beta}$ (min)	122 (99-139)	118 (97-172)
V_1 (mL/kg)	117 (112-163)	147 (112-173)
V_2 (mL/kg)	356 (263-492)	298 (287-561)
V_{ss} (mL/kg)	491 (379-604)	462 (403-714)
CL (mL/min/kg)	3 (2-4.5)	2.8 (2.1-4.8)
CL _D (mL/min/kg)	23.9 (20.1-43)	33.6 (20.5-43.7)
K_{10} (/min)	0.023 (0.017-0.04)	0.02 (0.015-0.031)*
$K_{10} T_{1/2}$ (min)	29.6 (17.1-41)	34.2 (22.4-45.6)
K_{12} (/min)	0.199 (0.141-0.379)	0.268 (0.139-0.367)
K_{21} (/min)	0.072 (0.059-0.115)	0.075 (0.062-0.147)
C_0 (ng/mL)	2558.2 (1842.9-2680)	4069.8 (3464.6-5345)
AUC (ng.min/mL)	100665 (66124-152054)	214892 (126217-281694)
AUMC (ng.min ² /mL)	16577189 (8802645-29246856)	33971353 (18959367-53741134)
MRT (min)	165 (133-192)	160 (130-236)

*Significantly (P<0.05) different from M300 (dose-dependent parameters were indexed

to the dose for comparison). See table 1 for remainder of key.

406Table 3: Mean±SD protein-binding of dexmedetomidine, with and without MK-467, and
 407MK-467, with and without dexmedetomidine, in cat plasma. Mean and SD were
 408calculated from triplicate measurements.

Drug and concentration	Fraction bound in plasma (%)
Dexmedetomidine 5 ng/mL	91.2±1.9
Dexmedetomidine 20 ng/mL	92.5±0.2
Dexmedetomidine 100 ng/mL	91.4±0.8
Dexmedetomidine 20 ng/mL with MK-467 0.1 µg/mL	92.2±0.4
Dexmedetomidine 20 ng/mL with MK-467 1 µg/mL	92.3±0.6
Dexmedetomidine 20 ng/mL with MK-467 10 µg/mL	92.8±0.4
MK-467 0.1 µg/mL	53.5±5.9
MK-467 1 µg/mL	65.8±3.4
MK-467 10 µg/mL	64.4±3.8
MK-467 0.1 µg/mL with dexmedetomidine 20 ng/mL	56.1±2.6
MK-467 1 µg/mL with dexmedetomidine 20 ng/mL	65.9±5
MK-467 10 µg/mL with dexmedetomidine 20 ng/mL	64.1±8.1

409

410Figure legends

411

412Figure 1: Observed (markers) and predicted (lines) plasma dexmedetomidine

413concentrations following intravenous bolus administration of 12.5 µg/kg (D12.5), 25

414µg/kg (D25), or 25 µg/kg dexmedetomidine combined with 600 µg/kg MK-467

415(D25M600) in 7 cats. Due to a treatment error, data is only available in 6 cats for D25.

417Figure 2: Observed (markers) and predicted (lines) plasma MK-467 concentrations
418following intravenous bolus administration of 300 µg/kg (M300), or 600 µg/kg MK-467
419combined with 25 µg/kg dexmedetomidine (D25M600) in 7 cats.